{"_links": {"parentPackage": {"href": "/mdr/ct/packages/sdtmct-2022-09-30", "title": "SDTM Controlled Terminology Package 51 Effective 2022-09-30", "type": "Terminology"}, "priorVersion": {"href": "/mdr/ct/packages/sdtmct-2022-06-24/codelists/C125922", "title": "CDISC SDTM Microscopic Findings Test Detail Terminology", "type": "Code List"}, "rootItem": {"href": "/mdr/root/ct/sdtmct/codelists/C125922", "title": "Version-agnostic anchor resource for codelist C125922", "type": "Root Value Domain"}, "self": {"href": "/mdr/ct/packages/sdtmct-2022-09-30/codelists/C125922", "title": "CDISC SDTM Microscopic Findings Test Detail Terminology", "type": "Code List"}}, "conceptId": "C125922", "definition": "Terminology relevant to the additional descriptions of the test being performed to produce the microscopic result.", "extensible": "true", "name": "Microscopic Findings Test Details", "preferredTerm": "CDISC SDTM Microscopic Findings Test Detail Terminology", "submissionValue": "MIFTSDTL", "synonyms": ["Microscopic Findings Test Details"], "terms": [{"conceptId": "C135461", "definition": "A grading system developed by the American Joint Committee on Cancer (AJCC) and assigned based on the degree of cellular differentiation within a tumor sample.", "preferredTerm": "AJCC Tumor Grade", "submissionValue": "AJCC TUMOR GRADE"}, {"conceptId": "C125985", "definition": "A score developed by Allred et al. (1998) and assigned based on the percent positivity of cells for a particular protein (Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68).", "preferredTerm": "Allred Proportion Positive Score", "submissionValue": "ALLRED PROPORTION POSITIVE SCORE"}, {"conceptId": "C125986", "definition": "A score developed by Allred et al. (1998) and assigned based on the average staining intensity of cells for a particular protein (Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68).", "preferredTerm": "Allred Average Staining Intensity Score", "submissionValue": "ALLRED STAINING INTENSITY SCORE"}, {"conceptId": "C125987", "definition": "The histopathological evaluation of staining in tissue based on the Allred scoring system (Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998 Feb;11(2):155-68).", "preferredTerm": "Allred Total Score", "submissionValue": "ALLRED TOTAL SCORE"}, {"conceptId": "C135462", "definition": "A score originally developed by Solez et al. (1993) and assigned based on the histologic evaluation of kidney allograft biopsies according to the Banff Working Classification of Renal Allograft Pathology.", "preferredTerm": "Banff Renal Quantitative Criteria Score", "submissionValue": "BANFF QUANTITATIVE CRITERIA SCORE RENAL"}, {"conceptId": "C119570", "definition": "The histopathological evaluation of the liver based on the Batts-Ludwig scoring system.", "preferredTerm": "Batts-Ludwig Fibrosis Score", "submissionValue": "BATTS-LUDWIG FIBROSIS SCORE", "synonyms": ["Batts-Ludwig Fibrosis Score"]}, {"conceptId": "C154808", "definition": "A score based on the Bauermeister scale, a 6-point grading system used to rate the extent of myelofibrosis, based on the amount of reticulin and collagen fibers present in the bone marrow. (Bauermeister DE. Quantitation of bone marrow reticulin-a normal range. Am J Clin Pathol. 1971 Jul;56(1):24-31.)", "preferredTerm": "Bauermeister Score", "submissionValue": "BAUERMEISTER SCORE"}, {"conceptId": "C181467", "definition": "A grading system developed by the College of American Pathology to assess a decrease in tumor size or extent in the body. (College of American Pathology)", "preferredTerm": "College of American Pathology Tumor Regression Grade", "submissionValue": "CAP TUMOR REGRESSION GRADE", "synonyms": ["College of American Pathology Tumor Regression Grade"]}, {"conceptId": "C158254", "definition": "A microscopic measurement of the volumetric or area ratios of components (e.g. blood vessel-, macrophage-, or lymphatic vessel density) of tissues or organs. (Chalkley HW. Method for the quantitative morphological analysis of tissues. J Natl Cancer Inst; 4: 47-52)", "preferredTerm": "Chalkley Score", "submissionValue": "CHALKLEY SCORE"}, {"conceptId": "C132429", "definition": "The histopathological evaluation of the liver based on the enhanced liver fibrosis scoring system.", "preferredTerm": "Enhanced Liver Fibrosis Score", "submissionValue": "ENHANCED LIVER FIBROSIS SCORE", "synonyms": ["ELF"]}, {"conceptId": "C154809", "definition": "A score based on the European Consensus scale, a 4-point grading system for the qualitative and quantitative evaluation of bone marrow fibrosis. (Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug;90(8):1128-32.)", "preferredTerm": "European Consensus Score For Bone Marrow Fibrosis", "submissionValue": "EUROPEAN CONSENSUS SCORE"}, {"conceptId": "C181469", "definition": "A grading system developed by Evans et al (1992) to assess a decrease in tumor size or extent in the body. (Evans DB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg. (1992) 127:1335-9.)", "preferredTerm": "Evans et al Tumor Regression Grade (1992)", "submissionValue": "EVANS TUMOR REGRESSION GRADE 1992"}, {"conceptId": "C187943", "definition": "A tumor histopathologic grading system developed by Bhatla et al (2018) for uterine and cervical cancers. (Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri. Int J Gynaecol Obstet 2018;143(Suppl 2):22-36.)", "preferredTerm": "FIGO Tumor Grade", "submissionValue": "FIGO TUMOR GRADE"}, {"conceptId": "C62411", "definition": "A tumor grading system developed by Fuhrman et al (1982) that evaluates nuclear grade, based on nuclear size, irregularity and nucleolar prominence, in renal cell carcinomas. (Fuhrman SA, Lasky SA, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982 Oct;6(7):655-63.)", "preferredTerm": "Fuhrman Nuclear Grade", "submissionValue": "FUHRMAN NUCLEAR GRADE", "synonyms": ["Fuhrman Tumor Grade"]}, {"conceptId": "C178033", "definition": "A score originally developed by D'Haens et al. (1998) and assigned based on the histologic evaluation of acute and chronic inflammatory changes, epithelial damage, and the extent of inflammation in Crohn's disease mucosal biopsy specimens, according to the Global Histologic Disease Activity Score. (G R D'Haens, K Geboes, M Peeters, F Baert, F Penninckx, P Rutgeerts. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology. 1998 Feb;114(2):262-7).", "preferredTerm": "Global Histologic Disease Activity Score", "submissionValue": "GHAS SCORE", "synonyms": ["Global Histologic Disease Activity Score"]}, {"conceptId": "C48603", "definition": "The most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. (Gleason, D. F. (1977). The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum, M. Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger. pp. 171-198.)", "preferredTerm": "Primary Gleason Pattern", "submissionValue": "GLEASON PRIMARY SCORE"}, {"conceptId": "C48604", "definition": "The second most prevalent Gleason pattern in a prostate biopsy or prostatectomy specimen. (Gleason, D. F. (1977). The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum, M. Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger. pp. 171-198.)", "preferredTerm": "Secondary Gleason Pattern", "submissionValue": "GLEASON SECONDARY SCORE"}, {"conceptId": "C48602", "definition": "The sum of the primary and secondary Gleason scores. If three patterns are identified, it is the sum of the primary pattern score and the score of the least well-differentiated pattern. (Gleason, D. F. (1977). The Veteran's Administration Cooperative Urologic Research Group: histologic grading and clinical staging of prostatic carcinoma. In Tannenbaum, M. Urologic Pathology: The Prostate. Philadelphia: Lea and Febiger. pp. 171-198.)", "preferredTerm": "Total Gleason Score for Prostate Cancer", "submissionValue": "GLEASON TOTAL SUM"}, {"conceptId": "C181473", "definition": "A measurement of the amount or proportion of cells that have a staining intensity of 0, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).", "preferredTerm": "H Score Staining Intensity 0", "submissionValue": "H SCORE STAINING INTENSITY 0"}, {"conceptId": "C181474", "definition": "A measurement of the amount or proportion of cells that have a staining intensity of 1+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).", "preferredTerm": "H Score Staining Intensity 1+", "submissionValue": "H SCORE STAINING INTENSITY 1+"}, {"conceptId": "C181475", "definition": "A measurement of the amount or proportion of cells that have a staining intensity of 2+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).", "preferredTerm": "H Score Staining Intensity 2+", "submissionValue": "H SCORE STAINING INTENSITY 2+"}, {"conceptId": "C181476", "definition": "A measurement of the amount or proportion of cells that have a staining intensity of 3+, based on the H Score scoring system, in a biological specimen. (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).", "preferredTerm": "H Score Staining Intensity 3+", "submissionValue": "H SCORE STAINING INTENSITY 3+"}, {"conceptId": "C125988", "definition": "The histopathological evaluation of staining in tissue based on the H Score scoring system (McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses: correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109(8):716-721).", "preferredTerm": "H Score Total Score", "submissionValue": "H SCORE TOTAL SCORE"}, {"conceptId": "C181470", "definition": "A grading system developed by Hartman et al (2012) to assess a decrease in tumor size or extent in the body. (Hartman DJ, Krasinskas AM. Assessing treatment effect in pancreatic cancer. Arch Pathol Lab Med. (2012) 136:100-9.)", "preferredTerm": "Hartman et al Tumor Regression Grade (2012)", "submissionValue": "HARTMAN TUMOR REGRESSION GRADE 2012"}, {"conceptId": "C189619", "definition": "A classification for grading and staging of neuroendocrine neoplasms published by the World Health Organization (WHO) in 2018. (Rindi, G., Klimstra, D.S., Abedi-Ardekani, B. et al. A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal. Mod Pathol 31, 1770-1786 (2018).)", "preferredTerm": "IARC and WHO Classification of Tumors of Neuroendocrine Neoplasms 2018", "submissionValue": "IARC AND WHO CLASSIFICATION OF NEUROENDOCRINE NEOPLASMS 2018"}, {"conceptId": "C181471", "definition": "A grading system developed by Dworak et al (1997) to assess a decrease in tumor size or extent in the body. (Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis. (1997) 12:19-23.)", "preferredTerm": "iDworak et al Tumor Regression Grade (1997)", "submissionValue": "IDWORAK TUMOR REGRESSION GRADE 1997"}, {"conceptId": "C95149", "definition": "The histopathological evaluation of the liver based on the Ishak scoring system.", "preferredTerm": "Ishak Score", "submissionValue": "ISHAK FIBROSIS SCORE", "synonyms": ["Ishak Fibrosis Score"]}, {"conceptId": "C142346", "definition": "A grading system for prostatic adenocarcinoma based on cellular differentiation patterns and Gleason primary and secondary scores (Epstein JI, Egevad L, Amin MB, Delahunt B, Srigley JR, Humphrey PA; Grading Committee. The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. Am J Surg Pathol. 2016 Feb;40(2):244-52.)", "preferredTerm": "International Society of Urological Pathology Gleason Grade Group", "submissionValue": "ISUP GLEASON GRADE GROUP"}, {"conceptId": "C187944", "definition": "A classification system for rectal cancer prognosis based on four histomorphologic parameters. (JR Jass, SB Love, JM Northover. A new prognostic classification of rectal cancer. Lancet 1987 Jun 6;1(8545):1303-6.)", "preferredTerm": "JASS Rectal Cancer Prognostic Classification 1987", "submissionValue": "JASS RECTAL CANCER PROGNOSTIC CLASSIFICATION 1987"}, {"conceptId": "C119571", "definition": "The histopathological evaluation of the liver based on the Knodell scoring system.", "preferredTerm": "Knodell Fibrosis Score", "submissionValue": "KNODELL FIBROSIS SCORE", "synonyms": ["Knodell Fibrosis Score"]}, {"conceptId": "C181468", "definition": "A grading system developed by Chatterjee et al (2012) to assess a decrease in tumor size or extent in the body. (Chatterjee D, Katz MH, Rashid A, Wolff RA, Wang H, Lee JE, et al. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome. Cancer. (2012) 118:3182-90.)", "preferredTerm": "MD Anderson Tumor Regression Grade (2012)", "submissionValue": "MD ANDERSON TUMOR REGRESSION GRADE 2012"}, {"conceptId": "C119572", "definition": "The histopathological evaluation of the liver based on the Meta-analysis of Histological Data in Viral Hepatitis (Metavir) scoring system.", "preferredTerm": "METAVIR Fibrosis Score", "submissionValue": "METAVIR FIBROSIS SCORE", "synonyms": ["Metavir Fibrosis Score"]}, {"conceptId": "C174344", "definition": "The histopathological evaluation of MET (Hepatocyte Growth Factor Receptor) staining in tissue based on the METMAB scoring system (Koeppen H, Yu W, Zha J, et al. Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib +/- Onartuzumab in Advanced Non-Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit. Clin Cancer Res. 2014 September 1; 20(17): 4488-4498.)", "preferredTerm": "METMAB Score", "submissionValue": "METMAB SCORE"}, {"conceptId": "C181472", "definition": "The histopathological evaluation of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) based on the NAFLD activity scoring system (NAS). (Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ; Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21.)", "preferredTerm": "Non-Alcoholic Fatty Liver Disease Activity Score", "submissionValue": "NAFLD ACTIVITY SCORE", "synonyms": ["NAS", "Non-Alcoholic Fatty Liver Disease Activity Score"]}, {"conceptId": "C138986", "definition": "A histologic grading system developed by Elston and Ellis as a modification of the Scarff-Bloom-Richardson grading system, based on tubule formation, nuclear pleomorphism, and mitotic counts of invasive adenocarcinomas. (CW Ellston, O Ellis. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991 Nov;19(5):403-10.)", "preferredTerm": "Nottingham Grade", "submissionValue": "NOTTINGHAM HISTOLOGIC GRADE", "synonyms": ["Elston-Ellis modification of Scarff-Bloom-Richardson Grading System"]}, {"conceptId": "C70460", "definition": "A measurement of the proportion of cells that are positive for a given protein.", "preferredTerm": "Percent of Positive Cells", "submissionValue": "PERCENT POSITIVE CELL"}, {"conceptId": "C156548", "definition": "A measurement of the total number of cells that stain positively in a biological specimen.", "preferredTerm": "Positive Cell Count", "submissionValue": "POSITIVE CELL COUNT"}, {"conceptId": "C125989", "definition": "An assessment of the status of a biological specimen with regards to a given receptor.", "preferredTerm": "Receptor Overall Status", "submissionValue": "RECEPTOR OVERALL STATUS"}, {"conceptId": "C178034", "definition": "A score developed by Mosli et al. (2017) and assigned based on the histologic evaluation of disease activity in ulcerative colitis. (Mahmoud H Mosli, Brian G Feagan, Guangyong Zou, et al. Development and validation of a histological index for UC. Gut. 2017 Jan;66(1):50-58.)", "preferredTerm": "Robarts Histopathology Index Score", "submissionValue": "RHI SCORE", "synonyms": ["Robarts Histopathology Index Score"]}, {"conceptId": "C119573", "definition": "The histopathological evaluation of the liver based on the Scheuer scoring system.", "preferredTerm": "Scheuer Fibrosis Score", "submissionValue": "SCHEUER FIBROSIS SCORE", "synonyms": ["Scheuer Fibrosis Score"]}, {"conceptId": "C186199", "definition": "A measurement of the amount or proportion of tissue or cells that have a staining intensity of 0.", "preferredTerm": "Staining Intensity 0", "submissionValue": "STAINING INTENSITY 0"}, {"conceptId": "C186200", "definition": "A measurement of the amount or proportion of tissue or cells that have a staining intensity of 1+.", "preferredTerm": "Staining Intensity 1+", "submissionValue": "STAINING INTENSITY 1+"}, {"conceptId": "C186201", "definition": "A measurement of the amount or proportion of tissue or cells that have a staining intensity of 2+.", "preferredTerm": "Staining Intensity 2+", "submissionValue": "STAINING INTENSITY 2+"}, {"conceptId": "C186202", "definition": "A measurement of the amount or proportion of tissue or cells that have a staining intensity of 3+.", "preferredTerm": "Staining Intensity 3+", "submissionValue": "STAINING INTENSITY 3+"}, {"conceptId": "C127762", "definition": "The degree or magnitude of staining within a biological specimen.", "preferredTerm": "Staining Intensity", "submissionValue": "STAINING INTENSITY"}, {"conceptId": "C154810", "definition": "The percentage of viable tumor cells with partial or complete cell membrane staining.", "preferredTerm": "Tumor Proportion Score", "submissionValue": "TUMOR PROPORTION SCORE"}, {"conceptId": "C189617", "definition": "A classification for grading and staging of tumors of endocrine organs published by the World Health Organization (WHO) in 2017. (Lloyd RV, Osamura R, Kloppel G, Rosai J. WHO Classification of Tumours of Endocrine Organs. 4th ed. Lyon: IARC Press; 2017.)", "preferredTerm": "WHO Classification of Tumors of Endocrine Organs 2017", "submissionValue": "WHO CLASSIFICATION OF TUMORS OF ENDOCRINE ORGANS 2017"}, {"conceptId": "C189616", "definition": "A classification for grading and staging of tumors of the digestive system published by the World Health Organization (WHO) in 2010. (Bosman F, Carneiro F: World Health Organization Classification of Tumours, Pathology and Genetics of Tumours of the Digestive System., Lyon: IARC Press, 2010.)", "preferredTerm": "WHO Classification of Tumors of the Digestive System 2010", "submissionValue": "WHO CLASSIFICATION OF TUMORS OF THE DIGESTIVE SYSTEM 2010"}, {"conceptId": "C189618", "definition": "A classification for grading and staging of tumors of the digestive system published by the World Health Organization (WHO) in 2019. (Iris D Nagtegaal, Robert D Odze, David Klimstra, Valerie Paradis, Massimo Rugge, Peter Schirmacher, Kay M Washington, Fatima Carneiro, Ian A Cree, and the WHO Classification of Tumours Editorial Board. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2020 Jan; 76(2): 182-188.)", "preferredTerm": "WHO Classification of Tumors of the Digestive System 2019", "submissionValue": "WHO CLASSIFICATION OF TUMORS OF THE DIGESTIVE SYSTEM 2019"}, {"conceptId": "C187945", "definition": "A tumor grading system developed by the members of the ISUP Renal Tumor Panel (2013) that evaluates nuclear grade in renal cell carcinomas. (Delahunt B., Cheville J.C., Martignoni G., Humphrey P.A., Magi-Galluzzi C., McKenney J., Egevad L., Algaba F., Moch H., Grignon D.J., Montironi R., Srigley J.R., Members of the ISUP Renal Tumor Panel. International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37:1490-1504.)", "preferredTerm": "WHO/ISUP Fuhrman Nuclear Grade", "submissionValue": "WHO/ISUP NUCLEAR GRADE", "synonyms": ["WHO/ISUP Tumor Grade"]}]}